"Risks and Rewards: The Truth About New Alzheimer's Drugs"

Scientists are warning against the approval of drugs like lecanemab and donanemab for Alzheimer's disease, citing risks such as brain shrinkage, swelling, and bleeding. While these drugs claim to slow cognitive decline by clearing out amyloid protein, they have been associated with serious side effects, including fatal outcomes and significant brain volume loss. The marginal improvement in cognitive function does not outweigh the potential harm, raising concerns about the utility of these treatments.